The Lancet Oncology10.1016/s1470-2045(20)30012-72020212203Chemotherapy for resectable microsatellite instability-high gastric cancer?Florian Lordick,
The Lancet Oncology10.1016/s1470-2045(20)30025-52020212204Chemotherapy for resectable microsatellite instability-high gastric cancer?Elizabeth C Smyth,
10.21203/ Chemotherapy for Gastric Cancer Patients with Mismatch Repair Deficiency or Microsatellite Instability: Systematic Review and Meta-AnalysisRuncong Nie, Shuqiang Yuan, Jin Won Kim, Yun Wang, Guoming Chen, Jie Zhou, Yingbo Chen, Shi Chen, Zhiwei Zhou, Muyan Cai, Yuanfang Li,
Clinical Colorectal Cancer10.1016/s1533-0028(11)70320-6200223146-148Lack of Benefit of 5-Fluorouracil-Based Adjuvant Chemotherapy in Colorectal Cancer with Microsatellite InstabilityLori Johnson, Edward Chu,
Gastric Cancer - An Update10.5772/intechopen.798242019Adjuvant Chemotherapy of Gastric CancerByoung Jo Suh
Current Colorectal Cancer Reports10.1007/s11888-011-0105-2201174260-266Application of Microsatellite Instability and Oncotype DX in Stage II Colon Cancer Adjuvant ChemotherapyEdward Chu,,
Gastroenterology10.1053/gast.2001.23646200112051309Microsatellite instability as a molecular marker for very good survival in colorectal cancer patients receiving adjuvant chemotherapyHany Elsaleh, Bev Shannon, Barry Iacopetta,
Clinical Colorectal Cancer10.3816/ccc.2001.n.010200112104-109Microsatellite Instability Is a Predictive Marker for Survival Benefit from Adjuvant Chemotherapy in a Population-Based Series of Stage III Colorectal CarcinomaHany Elsaleh, Barry Iacopetta,
Journal of Gastric Cancer10.5230/jgc.2012.12.1.320121213Update of Adjuvant Chemotherapy for Resected Gastric CancerSang Cheul Oh,,
European Journal of Cancer10.1016/s0959-8049(02)80039-920023811S40-S41Microsatellite instability: A predictor of outcome in gastric cancer in a high-frequent areaM Yaghoobi,